ParticipantsCyrus Raji, MD,PhD, St. Louis, MO (Moderator) Consultant, Brainreader ApS
Jody L. Tanabe, MD, Aurora, CO (Moderator) Nothing to Disclose
1) Enhance radiologist understanding in current clinical applications of structural and functional hippocampal imaging in Alzheimer's disease. 2) Overview MR imaging findings in non-Alzheimer's causes of dementia such as Creutzfeldt-Jakob disease and normal pressure hydrocephalus. 3) Update radiologists about neuronuclear techniques in Alzheimer's disease such as FDG PET and amyloid PET. 4) Overview correlative structural and functional neuroimaging findings in the neuropsychological characterization of dementia with a focus on non-Alzheimer's dementia such as frontal temporal dementia.
ParticipantsMichael M. Zeineh, PhD, MD, Stanford, CA (Presenter) Research funded, General Electric Company; Consultant, Biogen Idec Inc
1) Describe the benefits of advanced forms of imaging (e.g. 7T MRI, DTI, fMRI). 2) Identify major issues around neuroimaging in AD. C) Appraise potential benefits of advanced neuroimaging in AD.
ParticipantsLeo P. Sugrue, MD, PhD, San Francisco, CA (Presenter) Nothing to Disclose
1) To use clinical history to narrow the dementia differential. 2) To identify imaging findings in CJD. 3) To recognize CJD mimics. 4) To identify imaging findings in NPH. 5) To explain the difference between NPH and communicating hydrocephalus.
ParticipantsJames M. Mountz, MD, PhD, Pittsburgh, PA (Presenter) Nothing to Disclose
1) To describe the physiologic characteristics of F-18 FDG and Amyloid imaging binding agents as it's related to imaging findings in dementia. 2) To explain the imaging methods and scan findings that are obtained in normal and Alzheimer's disease patients as compared to normal controls. 3) To show imaging characteristics in other dementias that have cognitive symptomatology which are similar to those of patients with Alzheimer's disease.
ParticipantsJohn L. Ulmer, MD, Milwaukee, WI (Presenter) Stockholder, Prism Clinical Imaging, Inc; Medical Advisory Board, General Electric Company
1) To familiarize with current classification of Alzheimer's Disease and Frontotemporal Lobe Degeneration. 2) Come to know the challenges faced by Neurologist and Neuropsychologist in diagnosing dementias. 3) Understand potential for imaging biomarkers in supporting diagnosis of Alzheimer's Disease and Frontotemporal lobe dementias.Active Handout:John L. Ulmer
http://abstract.rsna.org/uploads/2018/18002521/Clinical Classifications, Diagnostic Dilemmas RC105D.pdf